Clinical Testing of Pan-TRK Inhibitor Progresses Across Multiple Tumor Types

Ariela Katz
Published: Monday, Feb 12, 2018
Dr Alexander Drilon
Alexander Drilon, MD
The pan-TRK inhibitor entrectinib (RXDX101) is being tested simultaneously in multiple locally advanced or metastatic solid tumor types as a treatment for patients harboring fusions involving the NTRK1/2/3, ROS1, or ALK genes.

 

Figure. Entrectinib in Solid Tumors With NTRK1/2/3, ROS1, or ALK Gene Fusions

entrectinib-figure.jpg
Additionally, investigators are allowing patients with CNS involvement, including leptomeningeal carcinomatosis, that is either asymptomatic or previously treated and controlled. This is because entrectinib has demonstrated active coverage of the CNS, according to Alexander Drilon, MD, a medical oncologist and principal investigator for STARTRK-2 at Memorial Sloan Kettering Cancer Center in New York, New York. One patient with SQSTM1-NTRK1-rearranged lung cancer achieved a complete CNS response, and entrectinib was identified as a CNS-penetrant drug.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x